| 注册
首页|期刊导航|中国临床药理学杂志|N-乙酰半胱氨酸治疗AECOPD合并呼吸衰竭患者的临床研究

N-乙酰半胱氨酸治疗AECOPD合并呼吸衰竭患者的临床研究

马群 李卫阳 许蒙 陈慧 王婧

中国临床药理学杂志2025,Vol.41Issue(5):606-610,5.
中国临床药理学杂志2025,Vol.41Issue(5):606-610,5.DOI:10.13699/j.cnki.1001-6821.2025.05.002

N-乙酰半胱氨酸治疗AECOPD合并呼吸衰竭患者的临床研究

Clinical trial of N-acetylcysteine in the treatment of patients with AECOPD and respiratory failure

马群 1李卫阳 1许蒙 1陈慧 1王婧1

作者信息

  • 1. 南阳市第一人民医院呼吸与危重症医学二科,河南南阳 473000
  • 折叠

摘要

Abstract

Objective To observe the clinical effect and safety of N-acetylcysteine combined with budesonide and terbutaline in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)and respiratory failure(RF).Methods According to queuing method,patients with AECOPD and RF were divided into treatment group and control group.On basis of basic treatment,control group was given aerosol inhalation of budesonide suspension(1 mg/once,bid)and terbutaline solution(5 mg/once,bid),while treatment group was given aerosol inhalation of N-acetylcysteine solution(0.3 g/once,bid)on basis of control group.All patients were treated for 2 weeks.The clinical effect,pulmonary function indexes[forced vital capacity(FVC),peak expiratory flow(PEF)],dyspnea degree[modified version of British medical research council dyspnea scale(mMRC)],oxidative stress response indexes[superoxide dismutase(SOD)]and inflammatory response indexes[hypersensitive C-reactive protein(hs-CRP)]were compared between the two groups after treatment,and safety was evaluated.Results There were 56 cases in control group and 64 cases in treatment group.After treatment,the total effective rate of the treatment group and the control group were 93.75%(60 cases/64 cases)and 82.14%(46 cases/56 cases),respectively,and the difference was statistically significant(P<0.05).After treatment,FVC in treatment group and control group were(2.41±0.59)and(2.08±0.54)L;PEF were(4.97±1.18)and(4.08±1.12)L·s-1;mMRC scores were(1.86±0.39)and(2.67±0.56)points;SOD levels were(97.54±8.03)and(79.02±7.27)U·L-1;hs-CRP levels were(5.09±1.42)and(8.63±2.13)mg·L-1.Compared with control group,the above indexes in treatment group were statistically significant(all P<0.001).The adverse drug reactions in treatment group were mainly on vomiting,rash,palpitation and nausea,while in control group were mainly on fatigue,gastrointestinal reactions and rash.There was no significant difference in total incidence of adverse drug reactions between treatment group and control group[10.94%(7 cases/64 cases)vs 8.93%(5 cases/56 cases),P>0.05].Conclusion Curative effect of N-acetylcysteine combined with budesonide and terbutaline is significant in patients with AECOPD and RF,which can promote the recovery of pulmonary function,relieve dyspnea,oxidative stress and inflammatory response.

关键词

吸入用N-乙酰半胱氨酸溶液/布地奈德混悬液/特布他林雾化吸入用溶液/慢性阻塞性肺疾病急性加重期/呼吸衰竭/临床疗效

Key words

N-acetylcysteine solution for inhalation/budesonide suspension/terbutaline solution for inhalation/acute exacerbation of chronic obstructive pulmonary disease/respiratory failure/clinical effect

分类

药学

引用本文复制引用

马群,李卫阳,许蒙,陈慧,王婧..N-乙酰半胱氨酸治疗AECOPD合并呼吸衰竭患者的临床研究[J].中国临床药理学杂志,2025,41(5):606-610,5.

中国临床药理学杂志

OA北大核心

1001-6821

访问量5
|
下载量0
段落导航相关论文